Novartis Venture Fund

We are stage agnostic (seed to commercial companies) and invest in multiple therapeutic areas where there is a clear unmet medical need. Our first step in the process is to review non-confidential information about the company, team, technology/data, financial, and exit plan. The further evaluation of business proposals is then based on confidential presentations by the management team that starts the full due diligence process.